Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension

Having too low diastolic pressure could be linked to an increase in cardiovascular events (J-shape phenomenon). However, current guidelines suggest a target blood pressure under 130/80 mmHg with no lower limit for diastolic pressure.

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

This paper, recently published in JAMA, sought to evaluate the J-shape phenomenon of diastolic pressure in treated patients who reached a target systolic pressure under 130 mmHg—as guidelines recommend.

The cohort of patients was divided into the following intervals of diastolic pressure: less than 60 mmHg, between 60 and 70 mmHg, between 70 and 80 mmHg, and more than 80 mmHg.

The study’s primary endpoint was a composite of all-cause mortality, myocardial infarction, and stroke. The secondary endpoint included death due to cardiovascular causes, infarction, and non-fatal stroke.

The analysis included 7515 patients with a mean age of 65.6 years.

The lower risk for events was observed in patients with a diastolic pressure between 70 and 80 mmHg.


Read also: What to Do with Blood Pressure Levels Between 130/80 and 139/89 mmHg.


A mean diastolic pressure under 60 mmHg was linked to a significant increase in the primary endpoint risk (hazard ratio [HR]: 1.46; 95% confidence interval [CI]: 1.13-1.90; p = 0.004).

In relation to the composite, it was even more significant: death for cardiovascular causes (HR: 1.74; 95% CI: 1.26-2.41; p = 0.001), non-fatal stroke (HR: 1.73; 95% CI: 1.15-2.59; p = 0.008), and non-fatal stroke (HR 2.67; 95% CI: 1.26-5.63; p = 0.01).

Conclusion

This cohort study showed that a too low diastolic pressure (under 60 mmHg) was associated with an increase in cardiovascular events in treated patients who had reached a target systolic pressure of 130 mmHg or less.

The finding of an ideal systolic pressure between 70 and 80 mmH should be studied further.

li_2021_oi_201127_1612905985-33781

Original Title: Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.

Reference: Jingen Li et al. JAMA Network Open. 2021;4(2):e2037554. doi:10.1001/jamanetworkopen.2020.37554.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...